# A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia

> **NCT06433557** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ascendis Pharma Growth Disorders A/S** · enrollment: 22 (actual)

## Conditions studied

- Achondroplasia

## Interventions

- **DRUG:** Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections

## Key facts

- **NCT ID:** NCT06433557
- **Lead sponsor:** Ascendis Pharma Growth Disorders A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-26
- **Primary completion:** 2025-11-14
- **Final completion:** 2027-11
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06433557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06433557, "A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06433557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*